maritide amgen - Search News

News

Amgen, weight loss

Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its phase 3 trial.

Reuters on MSN · 4h

Amgen experimental weight-loss drug needs lower dose to limit side effects

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting on Monday that pushed the company's shares down nearly 6%.

Barron's on MSN · 6h

Amgen Shares Fall on Weight-Loss Drug Tummy Troubles

Amgen shares fell sharply on Monday afternoon after the company released results from a weight-loss trial that showed that lots of patients had stopped taking Amgen’s experimental weight loss shot after experiencing gastrointestinal distress.

Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...

STAT8h

Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing

Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...

Devdiscourse5h

Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns

Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...

Healio5h

Once-monthly dosing of novel GLP-1 agonist/GIP antagonist yields substantial weight loss

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results